Arcus Biosciences, Inc.

The biopharma sector saw another setback for the once-hot anti-TIGIT class on 3 April as BeiGene said it would end a Phase III trial of its antibody candidate ociperlimab (BGB-A1217) in non-small cell

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

Arcus Biosciences put a positive spin on Gilead Sciences’ decision not to opt in to further development of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC) on 18 February, no

The analytical tools encompassed by the concept of real-world evidence are growing increasingly valuable for enhancing early-stage drug development, an area receiving less attention than pivotal trial